CCL2 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Shows Divergent Prognostic Potential for Bladder Cancer Patients Depending on Lymph Node Stage.
CCL2
bladder cancer
immune cells
lymph node stage
prognosis
tumor cells
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
15 May 2020
15 May 2020
Historique:
received:
05
03
2020
revised:
29
04
2020
accepted:
11
05
2020
entrez:
21
5
2020
pubmed:
21
5
2020
medline:
21
5
2020
Statut:
epublish
Résumé
Bladder cancer (BCa) is the ninth most commonly diagnosed cancer worldwide. Although there are several well-established molecular and immunological classifications, markers for tumor cells and immune cells that are associated with prognosis are still needed. The chemokine CC motif ligand 2 (CCL2) could be such a marker. We analyzed the expression of CCL2 by immunohistochemistry (IHC) in 168 muscle invasive BCa samples using a tissue microarray. Application of a single cut-off for the staining status of tumor cells (TCs; positive vs. negative) and immune cells (ICs; ≤6% of ICs vs. >6% of ICs) revealed 57 cases (33.9%) and 70 cases (41.7%) with CCL2-positive TCs or ICs, respectively. IHC results were correlated with clinicopathological and survival data. Positive CCL2 staining in TCs was associated with shorter overall survival (OS), disease-specific survival (DSS), and relapse-free survival (RFS) (
Identifiants
pubmed: 32429318
pii: cancers12051253
doi: 10.3390/cancers12051253
pmc: PMC7281525
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Rudolf und Irmgard Kleinknecht-Stiftung
ID : none
Organisme : Johannes und Frieda Marohn-Stiftung
ID : none
Organisme : Wilhelm Sander-Stiftung
ID : 2015.171.1
Organisme : Deutsche Gesellschaft für Urologie (German Society of Urology)
ID : 14-07-11-1-Huppert
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Ann Hematol. 2019 Feb;98(2):413-422
pubmed: 30374624
Cancer Immunol Immunother. 2020 Jan;69(1):147-157
pubmed: 31900508
Cancer Cell. 2014 Feb 10;25(2):152-65
pubmed: 24525232
Tumour Biol. 2014 Jul;35(7):6601-5
pubmed: 24696263
Science. 2019 Nov 22;366(6468):1013-1021
pubmed: 31699883
N Engl J Med. 2020 Feb 27;382(9):869-871
pubmed: 32101671
Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3110-5
pubmed: 24520177
J Pathol Clin Res. 2017 Jan 13;3(1):58-70
pubmed: 28138402
Mol Med. 2015 May 13;21:371-80
pubmed: 25998509
Br J Urol. 1998 Jul;82(1):118-21
pubmed: 9698673
Front Oncol. 2019 Nov 20;9:1270
pubmed: 31824850
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Cancer Immunol Immunother. 2013 Mar;62(3):563-70
pubmed: 23090289
Eur Urol. 2019 Mar;75(3):423-432
pubmed: 30213523
Cancer Immunol Res. 2019 Jun;7(6):923-938
pubmed: 30988029
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3967-72
pubmed: 17360461
Cell Death Dis. 2019 Oct 14;10(10):781
pubmed: 31611552
Clin Genitourin Cancer. 2016 Dec;14(6):473-484
pubmed: 27209348
Eur Urol. 2014 Dec;66(6):1078-91
pubmed: 25151017
J Immunol. 2013 Jun 15;190(12):6673-80
pubmed: 23686489
Scand J Urol. 2017 Apr;51(2):87-94
pubmed: 28535714
Cancer Discov. 2017 Nov;7(11):1320-1335
pubmed: 28790030
Cancer Res. 2003 Nov 1;63(21):7451-61
pubmed: 14612545
BJU Int. 2020 Feb;125(2):270-275
pubmed: 31310696
Nat Commun. 2018 Sep 20;9(1):3826
pubmed: 30237493
Eur Urol. 2020 Apr;77(4):420-433
pubmed: 31563503
Adv Anat Pathol. 2017 Nov;24(6):311-335
pubmed: 28777143
Clin Cancer Res. 2012 Jun 15;18(12):3377-86
pubmed: 22553347
J Pathol. 2019 Apr;247(5):563-573
pubmed: 30604486
Eur Urol. 2017 Jan;71(1):96-108
pubmed: 27370177
Oncotarget. 2016 Feb 16;7(7):7842-55
pubmed: 26556868
Hepatology. 2013 Feb;57(2):829-39
pubmed: 23081697
Thyroid. 2009 Jan;19(1):21-5
pubmed: 19072670
Cell Mol Immunol. 2018 Apr;15(4):335-345
pubmed: 29375123
Eur Urol. 2019 Jul;76(1):59-68
pubmed: 30712971
Cancers (Basel). 2020 Jan 24;12(2):
pubmed: 31991604
J Cancer. 2019 Jan 1;10(3):697-707
pubmed: 30719168
Clin Cancer Res. 2000 Aug;6(8):3282-9
pubmed: 10955814
Oncotarget. 2018 Feb 19;9(19):15001-15014
pubmed: 29599921
Eur Urol. 2017 Oct;72(4):544-554
pubmed: 28390739
Cell. 2017 Oct 19;171(3):540-556.e25
pubmed: 28988769
Cancer Manag Res. 2018 Oct 23;10:4789-4804
pubmed: 30425573
Int J Cancer. 2014 Nov 1;135(9):2096-106
pubmed: 24676787
Cancer Res. 2007 Oct 1;67(19):9417-24
pubmed: 17909051
Nature. 2011 Jun 08;475(7355):222-5
pubmed: 21654748
Ann Transl Med. 2019 Sep;7(18):431
pubmed: 31700867
Transl Androl Urol. 2016 Oct;5(5):735-744
pubmed: 27785430
Cancer Med. 2016 Oct;5(10):2920-2933
pubmed: 27666332
Nat Rev Dis Primers. 2017 Apr 13;3:17022
pubmed: 28406148
Eur J Immunol. 2006 Feb;36(2):457-67
pubmed: 16421945
EBioMedicine. 2016 Oct;12:105-117
pubmed: 27612592
Urol Int. 2018;101(4):450-458
pubmed: 30189425
Urol Oncol. 2014 Aug;32(6):791-7
pubmed: 24794251